


Informed Consent and Returning Results in Whole-Exome Sequencing Protocols


Julie C. Sapp, ScM, CGC Genetic Counselor Genetic Disease Research Branch National Human Genome Research Institute

MEDICAL RECOR		RTICIPATE IN A CLINICAL RESEARCH STUDY t Patient or • Parent, for Minor Patient
INSTITUTE:	National Human Genome	e Research Institute
STUDY NUMBER:	10-HG-0065	PRINCIPAL INVESTIGATOR: Leslie G. Biesecker, MD
STUDY TITLE:	Whole Genome Medical	Sequencing for Gene Discovery
	pproved by the IRB on 12/0 ed by the IRB on 06/09/10 (B	
We invite you to tak	e part in a research study at	the National Institutes of Health (NIH).
First, we want you to	o know that:	
Taking part	in NIH research is entirely vo	oluntary.
	efits to which you are other	may withdraw from the study at any time. In either case, you will not wise entitled. However, to receive care at the NIH, you must be taking r study participation.
lose any ber	dy or be under evaluation fo	
lose any ber part in a stu		part. The research may give us knowledge that may help people in the











Outline

- Outline considerations in Whole-Exome Sequencing (WES) protocols
- Describe an approach to consent
- Discuss challenging populations and situations
- □ Explore options for returning results





- □ Informed consent as a process
- An opportunity for researcher-participant dialogue
 - Goals
 - Expectations
 - Plans
- Description of partnership
- Research goals drive informed consent process




Data: inherent uncertainty


- Data generated are a moving target
- □ Fully conveying scale and scope is impossible
- Impact on participants varies tremendously
 - Impact on investigators may be non-trivial


Outline


- General considerations in Whole-Exome Sequencing protocols (WES)
- □ Specific approach to consent
- □ Challenging populations and situations
- □ Returning results


ome se	auancing	g for gene discove	
	equencinq	g for gene discove	
MEDICAL RECORD		CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY Adult Patient or Parent, for Minor Patient	
INSTITUTE:	National Human Genome Rese	ational Human Genome Research Institute	
STUDY NUMBER:	10-HG-0065	PRINCIPAL INVESTIGATOR: Leslie G. Biesecker, MD	
STUDY TITLE:	Whole Genome Medical Sequer	ncing for Gene Discovery	
	proved by the IRB on 12/02/10 by the IRB on 06/09/10 (B)	Date Posted to Web: 01/07/11	
Standard			
We invite you to take		ational Institutes of Health (NIH).	
First, we want you to l	know that:		
Taking part in	NIH research is entirely voluntar	у.	
lose any bene		withdraw from the study at any time. In either case, you will not ntitled. However, to receive care at the NIH, you must be taking	




























Secondary Variants

- □ Autosomal recessive disorders
- Disease-causing mutations
 - Current/Future Onset
 - Treatment/Prevention
 - Surprising/Expected
- Uncertain significance
- Normal variation




Secondary variants


- □ Ancillary to research goal
- □ Annotation is time-consuming
- □ Annotation is ongoing
- Represents departure from traditional paradigms
- Impact will vary across participants
- □ May not even be generated!


Secondary variants


- □ Ancillary to research goal
- □ Annotation is time-consuming
- □ Annotation is ongoing
- Represents departure from traditional paradigms
- Impact will vary across participants
- □ May not even be generated!

Defy complete *a priori* delineation and categorization










Why so much detail?


- Return meaningful results to participants
- Enable participants to make informed decisions about results

Once you choose to know something, it is impossible to return to a state of ignorance






- General considerations in Whole-Exome Sequencing protocols (WES)
- □ Specific approach to consent
- □ Challenging populations and situations
- □ Returning results





Intellectual impairment


- Legal guardian/surrogate decision-maker
- Proof required prior to consent
- □ May require ethics consult

















Process

- Results possibilities reviewed, noted
- □ No commitment to preference at time of consent
- □ Annotation proceeds per study goal
- Participants re-contacted when available
- Categories reviewed and discussed
- Election made
- CLIA Validation
- □ Return to NIH for in-person review
 - May happen more than once

